Michaela Lehle

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

Bella Kaufman, John R. Mackey, Michael Clemens et al. · Journal of Clinical Oncology · 2009 · 850 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Eric Van Cutsem, Yung‐Jue Bang, Feng-yi Feng et al. · Gastric Cancer · 2014 · 609 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Steven W. Pipe, Midori Shima, Michaela Lehle et al. · The Lancet Haematology · 2019 · 385 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +5

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel et al. · Blood · 2020 · 289 citations · Full text

Medicine, Hematology, Pharmacotherapy +16